Regulatory approval
Published by the Health Canada. Approved
LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | BRCA1 pathogenic variants, HER2-negative | Invasive Breast Carcinoma | Olaparib | |
| HC (1) | BRCA2 pathogenic variants, HER2-negative | Invasive Breast Carcinoma | Olaparib |